Answers are grounded in this paper and cite their sources.
Real-world analysis shows adherence to GOLD 2023 recommendations reduces exacerbation risk in COPD, suggesting clinical practice improvements are needed.
In the real world, many patients with COPD do not receive the initial inhalation therapy recommended by the GOLD 2023 report. However, adherence to the GOLD 2023 report may decrease the risk of future exacerbation. It implied that improved the dissemination and uptake of GOLD 2023 recommendations is needed in the clinical practice.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: